Intended for healthcare professionals


Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials

BMJ 2000; 321 doi: (Published 16 December 2000) Cite this as: BMJ 2000;321:1519

A confusion between US and British abbreviations for drug doses led to an error in this paper by Michael Pignone and colleagues (21 October, pp 983-6). In the table (p 984) the drug doses shown for pravastatin (WOSCOPS) and lovastatin (AFCAPS/TexCAPS) should have been 40 mg once a day and 20-40 mg once a day, respectively [not four times daily]. In the second sentence of the third paragraph of the methods section (p 983) an analytical method was wrongly described; the sentence should read: “Meta-analysis was performed with the Mantel-Haenszel [not Peto] method for fixed effects models.”


View Abstract